Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias.
Porter JB, Lin KH, Beris P, Forni GL, Taher A, Habr D, Domokos G, Roubert B, Thein SL; EPIC study investigators. Porter JB, et al. Eur J Haematol. 2011 Oct;87(4):338-48. doi: 10.1111/j.1600-0609.2011.01660.x. Epub 2011 Jul 29. Eur J Haematol. 2011. PMID: 21649735 Free PMC article. Clinical Trial.
Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study.
Kwiatkowski JL, Hamdy M, El-Beshlawy A, Ebeid FSE, Badr M, Alshehri A, Kanter J, Inusa B, Adly AAM, Williams S, Kilinc Y, Lee D, Tricta F, Elalfy MS. Kwiatkowski JL, et al. Among authors: inusa b. Blood Adv. 2022 Feb 22;6(4):1243-1254. doi: 10.1182/bloodadvances.2021004938. Blood Adv. 2022. PMID: 34847228 Free PMC article. Clinical Trial.
Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study.
Hamdy M, El-Beshlawy A, Veríssimo MPA, Kanter J, Inusa B, Williams S, Lee D, Temin NT, Fradette C, Tricta F, Ebeid FSE, Kwiatkowski JL, Elalfy MS. Hamdy M, et al. Among authors: inusa b. Pediatr Blood Cancer. 2024 Jan;71(1):e30711. doi: 10.1002/pbc.30711. Epub 2023 Oct 9. Pediatr Blood Cancer. 2024. PMID: 37807937 Clinical Trial.
Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.
Vichinsky E, Bernaudin F, Forni GL, Gardner R, Hassell K, Heeney MM, Inusa B, Kutlar A, Lane P, Mathias L, Porter J, Tebbi C, Wilson F, Griffel L, Deng W, Giannone V, Coates T. Vichinsky E, et al. Among authors: inusa b. Br J Haematol. 2011 Aug;154(3):387-97. doi: 10.1111/j.1365-2141.2011.08720.x. Epub 2011 May 19. Br J Haematol. 2011. PMID: 21592110 Free PMC article. Clinical Trial.
A study of the geographic distribution and associated risk factors of leg ulcers within an international cohort of sickle cell disease patients: the CASiRe group analysis.
Antwi-Boasiako C, Andemariam B, Colombatti R, Asare EV, Strunk C, Piccone CM, Manwani D, Boruchov D, Farooq F, Urbonya R, Wilson S, Boatemaa GD, Perrotta S, Sainati L, Rivers A, Rao S, Zempsky W, Ekem I, Sey F, Segbefia C, Inusa B, Tartaglione I, Campbell AD. Antwi-Boasiako C, et al. Among authors: inusa b. Ann Hematol. 2020 Sep;99(9):2073-2079. doi: 10.1007/s00277-020-04057-8. Epub 2020 May 6. Ann Hematol. 2020. PMID: 32377816 Free PMC article.
117 results